Perrigo sells Dermacosmetics business to KKR-backed firm for up to €327 million
Investing.com -- Perrigo said on Monday it has agreed to sell its Dermacosmetics business to Kairos Bidco, an investment vehicle backed by KKR, for up to €327 million as part of its strategy to streamline its portfolio.
The deal includes €300 million in upfront cash payment and up to €27 million in milestone payments over a three-year period, according to the terms of the agreement.
The Dermacosmetics unit includes several brands such as ACO, Biodermal, Emolium and Iwostin.
The business generated net sales of approximately €125 million in 2024.
Perrigo plans to use the proceeds from the transaction for capital allocation priorities, including strengthening its balance sheet.
The transaction is expected to close in the first quarter of 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
With PRGO making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed PRGO alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including PRGO, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is PRGO poised for similar growth? Don't miss the opportunity to find out.
